Alx Oncology Holdings Inc. · NASDAQ:ALXO
Alx Oncology — Technical Presentation (January 2025)
12 slides from Alx Oncology's technical presentation, January 2025
Slide 1: ASPEN-06: Final analysis of the randomized phase 2 part of the ASPEN-06 study
ASPEN-06: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of Evorpacept (ALX148) , a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC) Kohei Shitara,1 Zev Wainberg,2 Josep Tabernero,3 Eric Van Cutsem,4
Slide 2: Evorpacept increases antibody dependent cellular phagocytosis in combination with trastuzumab without Fc-driven toxicity
Evorpacept increases antibody dependent cellular phagocytosis (ADCP) in combination with trastuzumab without Fc-driven toxicity Evorpacept, with an inactive Fc, binds and Inactive Fc spares normal cells, minimizing …maximizing the antibody dependent blocks CD47-SIRPα interaction toxicity… cellular p
Slide 3: ASPEN-06 is a global, randomized Phase 2/3 study of evorpacept plus TRP
ASPEN-06 is a global, randomized Phase 2/3 study which evaluated evorpacept plus TRP in 2nd and 3rd line GC/ GEJ patients Phase 2 portion Key eligibility criteria: Evorpacept ITT patients Primary objectives in both ITT N=127 T R P ▪ HER2+ GC or GEJ that has progressed on or and fresh biopsy populati
Slide 4: ASPEN-06: Patient Demographics
ASPEN-06: Patient Demographics Study population: ASPEN-06: patient demographics Evo T R P T R P N=63 N=64 • Patients with a fresh HER2+ Median age, years (range) 64 (34-81) 63 (31-86) biopsy underwent a biopsy at Male 55 (87.3%) 48 (75.0%) a median of 1.1 months Sex, n% before dosing (vs. 14.1 Femal
Slide 5: ORR, DOR in the ITT population
ASPEN-06: ORR, DOR in the ITT population Evo T R P T R P N evaluable 63 64 Confirmed ORR, n (%) 26 (41.3%) 17 (26.6%) [95% CI] [29.0%; 54.4%] [16.3%; 39.1%] CR (Complete Response) 1 ( 1.6%) 1 ( 1.6%) PR (Partial Response) 25 (39.7%) 16 (25.0%) SD (Stable Disease) 21 (33.3%) 35 (54.7%) PD (Progressiv
Slide 6: ORR, DOR and PFS in the ITT population
ASPEN-06: ORR, DOR and PFS in the ITT population Evo T R P T R P Evo + TRP N evaluable 63 64 TRP Confirmed ORR, n (%) 26 (41.3%) 17 (26.6%) [95% CI] [29.0%; 54.4%] [16.3%; 39.1%] CR (Complete Response) 1 ( 1.6%) 1 ( 1.6%) PR (Partial Response) 25 (39.7%) 16 (25.0%) SD (Stable Disease) 21 (33.3%) 35
Slide 7: Waterfall Plots: Tumor Size Reduction by Treatment Arm (ITT)
Waterfall Plots: Tumor Size Reduction by Treatment Arm (ITT) Evo T R P T R P ORR = 41.3% ORR = 26.6% (95% CI: 29%, 54%) (95% CI: 16%, 39%) 7 Data Cutoff as of 02 Dec 2024 ASCO GI 2025
Slide 8: Swimmer Plots: Duration of Response by Treatment Arm (ITT)
Swimmer Plots: Duration of Response by Treatment Arm (ITT) Evo T R P T R P mDOR = 15.7m mDOR = 9.1m (95% CI: 7.7m, NR) (95% CI: 5.3, NR) 8 Data Cutoff as of 02 Dec 2024 ASCO GI 2025
Slide 9: Anti-Tumor Response in confirmed HER2+ patients via fresh biopsy or ctDNA
ASPEN-06: Anti-Tumor Response (ORR and DOR) in confirmed HER2+ patients via fresh biopsy or ctDNA HER2+ confirmed with HER2+ confirmed with Fresh Biopsy Fresh Biopsy OR ctDNA+ Evo Evo T R P T R P T R P T R P N evaluable 22 26 47 49 Confirmed ORR, n (%) 13 (59.1%) 6 (23.1%) 23 (48.9%) 12 (24.5%) [95%
Slide 10: PFS by Treatment Arm in confirmed HER2+ patients via fresh biopsy or ctDNA
ASPEN-06: PFS by Treatment Arm in confirmed HER2+ patients via fresh biopsy or ctDNA Progression-free survival (PFS) based on investigator assessment HER2+ fresh biopsy (n=48) HER2+ (fresh biopsy OR ctDNA+) (n=96) Evo + TRP Evo + TRP TRP TRP Number of patients Number of patients mPFS [95% CI] Number
Slide 11: Safety
ASPEN-06: Safety Summary of treatment-emergent adverse events grades 3-5 (with frequency >5% on either arm) Evo T R P T R P • The incidence of adverse N=63 N=63 events due to any cause was Grade 3 4 5 3 4 5 comparable by arm Neutrophil count decreased 12 (19.0%) 7 (11.1%) - 12 (19.0%) 4 (6.3%) - • T
Slide 12: Conclusions
Conclusions • In the ITT population, the addition of evorpacept to TRP demonstrated an ORR of 41.3% and DOR of 15.7 months compared to the TRP control ORR of 26.6% and DOR of 9.1 months • Patients with confirmed HER2+ expression via either fresh biopsy or ctDNA received the greatest benefit in ORR,
ALX Oncology Holdings — Technical Presentation (January 2025) on 6ix